Fennec Pharmaceuticals Inc. (TSE:FRX) Director Chris Anigeron Rallis Sells 1,186 Shares

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Chris Anigeron Rallis sold 1,186 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of C$9.68, for a total transaction of C$11,485.70.

Fennec Pharmaceuticals Stock Performance

TSE FRX opened at C$9.80 on Monday. The firm’s fifty day moving average price is C$8.91 and its two-hundred day moving average price is C$7.72. The stock has a market cap of C$188.99 million, a PE ratio of -166.01 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a fifty-two week low of C$5.65 and a fifty-two week high of C$15.20. The company has a debt-to-equity ratio of -620.83, a quick ratio of 10.17 and a current ratio of 7.80.

Wall Street Analysts Forecast Growth

Separately, Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.